# C <del>(</del> N T R U M

# **Satin Creditcare Network**

# Weak AuM growth, provisions a key monitorable

Satin results were a miss on AuM growth (+14% YoY vs est. of 22%) though NII beat was led by NIM expansion. Disbursements/repayments were lower/higher to est. by 11%/10%. Opex downtick and assignment income protected PPoP which was in line at Rs1.07bn. Provisions almost tripled sequentially to Rs529mn driven by stress in upper Assam and demonetisation related write-offs. CE in Assam is improving (at 75-80% vs 50% in Nov'19). We see AuM growth to pick-up in FY21/22E to 25%. RoA/RoE is set to come in at 2.6%/19.4% in FY22E. Valuation at 0.6x is attractive. Roll forward to FY22E ABV, retain Buy but revise multiple/TP to 1.0x/Rs300 (1.5x/Rs410 earlier).

#### Q3FY20 results - Weak on AuM, PPOP in-line, provisions spike

NII at Rs1.3bn saw a QoQ uptick (beating est. by 13%) driven by reported QoQ NIM expansion of 54bps QoQ to 12.9%. There was a QoQ yield/cost improvement of 26b/27bps. AuM growth was a miss at +14.3% YoY (est. 21% YoY) to Rs63.9bn. Disbursements were lower to est. by 11% and repayments were higher by 10%. Assignment income at Rs556mn, again contributed a chunk to other income. Opex was slightly lower due to other expenses and PPoP was in line at Rs1.1bn. GNPA ratio was stable QoQ at 3.1% while ECL came in higher at 2.2% vs 1.7% QoQ as provisions spiked to Rs529mn (est. Rs200mn). Tax expense was lower (tax rate at 13%) due to DTA. Net profit was lower at Rs477mn (est. Rs627mn).

#### Quarterly lower net accretion to AuM might lead to muted FY20E AuM growth.

Disbursements at Rs19.0bn were lower as due to process improvements, rejection rates rose YoY from 15% to 18%. Also, higher repayments were faster at 30% of opening AuM (vs avg. 25% for the last 8 quarters) as scheduled repayments were concentrated in the Q2&Q3FY20. Usually H2 is stronger for Satin (H2 is ~40% higher than H1) and management interaction suggests that the disbursement pace has picked-up. Factoring in higher net accretion in Q4FY20 AuM, we lower our FY20 AuM growth to 12% YoY (vs 21% earlier). For FY21/22E each we see growth resuming back to 25% AuM growth. Owing to higher liquidity on the balance sheet and lower growth, NIM for FY20E might dip by 60bps YoY to 8.3% (vs est. 8.6% earlier).

#### Assam portfolio stress and demonetisation related write-offs led to provision spike

Provision spiked sequentially and of the Rs529mn, provisions for the upper Assam portfolio were Rs290mn and write-offs were Rs240mn. Assam stage-3 is Rs30mn which might escalate in Q4FY20. However, upper Assam CE which was 50% in Nov'19 during CAA/NRC protest, has improved to 75-80%. CE for rest of Assam is 99%. Assam exposure is 6.1% though on-book portfolio is Rs2.5bn. The company does not face any challenges in West Bengal (5.6% of GLP). We see provisions to remain elevated in Q4FY20E and raise our provision estimates to 3.1% for FY20E (vs 1.5% earlier). Valuation and risks

For FY20 we have trimmed our NII/AUM and raised our provision est. while for FY21 we increase provisions. FY20E/21E earnings cut is -23.1%/-23.6%. Near term MFI potential is intact but credit costs might be higher. Revise multiple to 1.0x (vs 1.5x earlier) due to the earnings cut, roll forward to FY22 ABV to arrive at a TP of Rs300 (Rs410 earlier). Maintain BUY on attractive valuations. Risks: higher opex and spike in NPA.

#### Financial and valuation summary

Q3FY20	Q3FY19	YoY (%)	Q2FY20	QoQ (%)	FY20E	FY21E	FY22E
1312	1356	(3.2)	1158	13.3	5,010	5,722	7,339
1079	1239	(12.9)	904	19.4	3,858	4,342	5,483
529	99	431.7	140	277.7	1,386	1,137	1,252
477	700	(31.9)	549	(13.1)	1,779	2,397	3,165
14.3	29.9	(15.6)	15.3	(1.0)	12.0	24.9	24.7
12.9	15.4	(2.5)	12.3	0.5	8.3	8.6	8.7
46.9	42.3	4.6	54.7	(7.8)	51.3	51.0	50.4
3.1	3.2	0.1	3.1	0.0	3.6	3.3	3.1
2.9	4.2	1.3	3.3	0.4	2.0	2.4	2.6
13.8	26.9	(13.1)	16.5	(2.7)	15.1	17.4	19.4
-	-	-	-	-	0.8	0.7	0.6
	1312 1079 529 477 14.3 12.9 46.9 3.1 2.9	1312   1356     1079   1239     529   99     477   700     14.3   29.9     12.9   15.4     46.9   42.3     3.1   3.2     2.9   4.2     13.8   26.9	1312   1356   (3.2)     1079   1239   (12.9)     529   99   431.7     477   700   (31.9)     14.3   29.9   (15.6)     12.9   15.4   (2.5)     46.9   42.3   4.6     3.1   3.2   0.1     2.9   4.2   1.3     13.8   26.9   (13.1)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

Source: Company, Centrum Research estimates

Please see Appendix for analyst certifications and all other important disclosures.

#### **Result Update**

India I Diversified Financials

#### 20 February 2020

# Buy

Target Price: Rs300 Price: Rs181 Forecast return: 66%


#### Market Data

Bloomberg:	SATIN IN
52 week H/L:	Rs398/182
Market cap:	Rs10bn
Shares outstanding:	52mn
Free float:	53.5%
Avg. daily vol. 3mth:	143,564
Source: Bloomberg	

#### Changes in the report

Rating:	Unchanged
Target Price:	To Rs300 from Rs410
EPS:	(23)% FY20E & (24)% FY21E
Source: Centrum Rese	earch

#### SATIN relative to Nifty Midcap 100



#### Shareholding pattern

	Dec-19	Sep-19	Jun-19	Mar-19
Promoter	30.2	29.7	29.7	27.9
FIIs	7.8	13.5	13.3	14.8
DIIs	25.3	23.2	23.9	21.7
Public/oth	36.8	33.6	33.1	35.6
Source: BSE				



Analyst, Banks, Diversified Financials +91 22 4215 9110 gaurav.jani@centrum.co.in



BFSI

Rahul Nandwani Associate, Banks, Diversified Financials +91 22 4215 9364 rahul.nandwani@centrum.co.in

# **Thesis Snapshot**

### **Estimate revisions**

YE Mar (Rs mn)	FY20E	FY20E	0∕aha	FY21E	FY21E	% ah a
te Mar (KS mn)	New	Old	% chg	New	Old	% chg
NII	5,010	5,339	(6.2)	5,722	5,950	(3.8)
PPoP	3,858	3,958	(2.5)	4,342	4,943	(12.2)
PAT	1,779	2,313	(23.1)	2,397	3,137	(23.6)
AUM growth (%)	12.0	21.4	(9.4)	24.9	25.2	(0.3)
GNPA	3.6	3.2	36bps	3.3	3.1	22bps

Source: Centrum Research estimates

# **Centrum estimates vs Actual results**

Q3FY20	Q3FY20	(0/)
	201120	(%)
1,312	1,166	12.5
1079	1071	0.8
477	627	(24.0)
14.3	21.9	(7.6)
	1079 477	1079   1071     477   627     14.3   21.9

Source: Bloomberg, Centrum Research estimates

#### Satin versus Nifty Midcap 100

	1m	6m	1 year
SATIN IN	(21.8)	(33.0)	(19.0)
Nifty Midcap 100	0.9	15.3	11.2
Source: Bloomberg, NSE			

# **Key assumptions**

YE Mar (Rs mn)	FY20E	FY21E	FY22E
AUM growth (%)	12.0	24.9	24.7
NIM (%)	8.3	8.6	8.7
Other inc / Assets (%)	4.6	4.7	4.4
Cost / Assets (%)	6.0	5.6	5.6
Provision costs	3.1	2.1	1.8

Source: Centrum Research estimates

#### Valuations

For FY20 we have trimmed our NII/AUM and raised our provision est. while for FY21 we increase provisions. FY20E/21E earnings cut is -23.1%/-23.6%. Near term MFI potential is intact but credit costs might be higher. Revise multiple to 1.0x (vs 1.5x earlier) due to the earnings cut, roll forward to FY22 ABV to arrive at a TP of Rs300 (Rs410 earlier). Maintain BUY on attractive valuations. Risks: higher opex and spike in NPA.

valuations	
FY22E ABVPS (Rs)	297.9
Historical P/ABV (x)	2.0
Premium assigned (%)	(50.0)
Ascribed P/ABV (x)	1.0
Fair value / share (Rs)	300



Sensitivity analysis

	Provision cost								
	+10bps	+5bps	Current	-5bps	-10bps				
-10bps	(3.6)	(2.8)	(2.0)	(1.2)	(0.4)				
-5bps	(2.6)	(1.8)	(1.0)	(0.2)	0.6				
Current	(1.6)	(0.8)	0.0	0.8	1.6				
+5bps	(0.6)	0.2	1.0	1.8	2.6				
+10bps	0.4	1.2	2.0	2.8	3.6				
	-5bps Current +5bps	-10bps (3.6)   -5bps (2.6)   Current (1.6)   +5bps (0.6)	+10bps   +5bps     -10bps   (3.6)   (2.8)     -5bps   (2.6)   (1.8)     Current   (1.6)   (0.8)     +5bps   (0.6)   0.2	+10bps   +5bps   Current     -10bps   (3.6)   (2.8)   (2.0)     -5bps   (2.6)   (1.8)   (1.0)     Current   (1.6)   (0.8)   0.0     +5bps   (0.6)   0.2   1.0	+10bps   +5bps   Current   -5bps     -10bps   (3.6)   (2.8)   (2.0)   (1.2)     -5bps   (2.6)   (1.8)   (1.0)   (0.2)     Current   (1.6)   (0.8)   0.0   0.8     +5bps   (0.6)   0.2   1.0   1.8				

Source: Bloomberg, Centrum Research estimates

#### Peer comparison

Commony	Mkt Cap	CAGR FY	19-FY22	E (%)		P/B	VPS			RoA	. (%)			Ro	E (%)	
Company	Rs bn	Total inc	PPOP	PAT	FY19	FY20E	FY21E	FY22E	FY19	FY20E	FY21E	FY22E	FY19	FY20E	FY21E	FY22E
Satin CreditCare	9.4	14.6	15.3	17.5	1.3	0.7	0.6	0.6	2.6	2.0	2.4	2.6	19.1	15.1	17.4	19.4
Ujjivan SFB	92.2	33.18	57.9	57.5	5.0	3.1	2.6	2.2	1.7	2.1	2.5	2.7	12.9	14.6	16.3	20.1
Equitas	39.0	26.4	70.6	58.2	1.9	1.4	1.2	1.0	1.2	1.5	1.8	1.9	7.5	10.9	13.6	16.3
Credit Access	140.6	17.4	18.8	20.9	4.5	4.3	3.5	2.8	4.1	3.4	2.8	2.9	17.0	17.3	18.8	20.2
Spandana	70.4	19.0	18.3	21.2	2.6	2.5	2.1	1.7	2.2	2.8	2.3	2.4	21.5	17.9	23.5	24.3

# Fig 1: Key concall takeaways and metrics

FY20E Guidance	Q3FY20	Q2FY20	Our Comments
AuM growth	-	20-25%	Satin had revised its AuM growth guidance to 20-25% in Q2FY20. Given the muted growth seen in Q3FY20 we do not foresee it achieving this target. We see AUM growth of 12.0% for FY20. Over FY19-22E, see an AuM CAGR of 20% over FY19-22E.
NIM	-	-	9MFY20 has seen muted on AuM growth for Satin owing to process rationalisation (leading to higher rejection) and scheduled repayments in the 3-9M maturity bucket. Slower credit off-take and faster repayments have led to higher liquidity on the balance sheet leading to an NIM drag. Hence we revise our FY20 NIM estimate lower to 8.3% (vs 8.6% earlier). As we expect growth to pick-up in FY21/22E we might see NIM improving to 8.6%/8.7%.
Opex	-	Opex efficiency to improve	Opex improved in Q3FY20 with cost to income improving to 47.5% QoQ from 54.4%. This was led by higher NII and lower other expenses. Given the branch and employee expansion in 9MFY20 and given that no chunky opex costs are expected we see opex to AuM ratio to improve from 6.0% to 5.6% over FY19-22E.
Provisions costs	-	-	Due to the negative surprise in the Assam portfolio, FY20 credit costs might see a spike and we raise our est. to 310bps (vs 150bps earlier). We see provisions to taper down to 210/180bps in FY21/22E.
Consol. PAT	-	Rs.2.6bn	Consol. PAT of Rs.2.6bn was guided for FY20. We see a standalone PAT of Rs1.8bn for FY20 as 9MFY20 earnings were marred by a spike in provisions. We see standalone PAT/RoA/RoE at Rs3.2bn/2.6%/19.4% in FY22E.

# Fig 2: Quarterly Financials

Profit & Loss (Rs mn)	Q4FY18	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20
Interest earned	2,713	3,045	3,152	3,022	2,575	2,715	2,627	2,728
Interest expended	1,440	1,533	1,681	1,666	1,510	1,506	1,468	1,416
Net interest income	1,273	1,512	1,472	1,356	1,065	1,209	1,158	1,312
Other income	64	49	316	792	726	614	825	745
Total income	1,337	1,561	1,788	2,148	1,791	1,824	1,983	2,057
Operating expenses	714	823	914	909	1,065	994	1,080	978
Employees	474	597	617	703	731	730	761	721
Others	240	227	298	206	333	265	318	257
Operating profit	623	738	874	1,239	726	829	904	1,079
Provisions	(2)	358	184	99	(121)	180	140	529
Profit before tax	625	380	690	1,139	847	649	764	550
Тах	213	129	246	439	292	236	215	74
Profit after tax	411	250	444	700	555	414	549	477
Balance sheet								
AUM (Rs mn)	50,848	54,002	55,612	55,900	63,740	64,670	64,140	63,900
AUM growth (%)	40.6	43.2	39.5	29.9	25.4	19.8	15.3	14.3
Total CRAR (%)	23.7	26.4	25.2	30.1	28.5	30.5	30.1	32.2
Profitability ratios (reported %)								
Gross yield	23.7	23.6	25.7	27.4	22.1	20.7	21.4	21.7
Financial cost	12.3	11.7	12.3	12.0	10.1	9.4	9.1	8.9
NIM	11.4	11.9	13.4	15.4	12.0	11.4	12.3	12.9
Opex ratio	6.1	6.3	6.9	6.5	7.1	6.4	6.7	6.0
Loan loss ratio	0.0	2.7	1.5	0.7	-0.8	1.1	0.9	3.4
ROA	2.8	1.5	2.6	4.2	3.3	2.5	3.3	2.9
Leverage	5.8	5.9	5.4	5.1	4.6	3.9	3.6	3.4
ROE	18.9	10.7	18.0	26.9	20.0	13.5	16.5	13.8
Cost to income	53.4	52.7	51.4	42.3	59.5	54.6	54.7	46.9
Asset quality ratios (%)								
GNPA	4.4	3.9	4.1	3.2	2.9	2.8	3.1	3.1
ECL	4.2	3.5	3.2	2.0	1.6	1.6	1.7	2.2

# 20 February 2020

P&L (Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Interest income	9,573	11,795	10,804	11,720	15,013
Interest expense	5,317	6,390	5,794	5,998	7,674
NII	4,256	5,405	5,010	5,722	7,339
Other income	194	1,935	2,908	3,139	3,721
Total income	4,450	7,340	7,918	8,861	11,060
Operating expenses	2,740	3,763	4,061	4,519	5,577
Employee	1,892	2,648	2,942	3,197	3,832
Others	848	1,115	1,118	1,322	1,745
РРОР	1,711	3,577	3,858	4,342	5,483
Provisions	445	521	1,386	1,137	1,252
РВТ	1,266	3,056	2,471	3,205	4,231
Tax	445	1,107	692	808	1,066
РАТ	821	1,949	1,779	2,397	3,165
Ratios	FY18	FY19	FY20E	FY21E	FY22E

Ratios	FY18	FY19	FY20E	FY21E	FY22E
Growth (%)					
AUM	40.6	25.3	12.0	24.9	24.7
Borrowings	14.0	9.2	(14.3)	24.4	32.6
NII	41.6	27.0	(7.3)	14.2	28.3
Other income	(52.6)	895.9	50.3	7.9	18.5
Opex	7.9	37.4	7.9	11.3	23.4
РРоР	95.1	109.1	7.9	12.6	26.3
Provisions	(12.0)	17.1	166.2	(18.0)	10.1
РАТ	235.3	137.3	(8.7)	34.7	32.0
Profitability ratios (%)					
Yield on IEA	18.1	19.5	17.9	17.5	17.9
Cost of funds	13.0	14.0	13.1	13.1	13.0
Spread	5.1	5.4	4.8	4.4	4.9
NIM	8.1	8.9	8.3	8.6	8.7
Other Income/ Total Income	4.4	26.4	36.7	35.4	33.6
Other Income / Total Assets	0.4	3.0	4.6	4.7	4.4
Cost / Income	61.6	51.3	51.3	51.0	50.4
Employees	42.5	36.1	37.2	36.1	34.7
Others	19.1	15.2	14.1	14.9	15.8
Opex / AuM	6.3	6.6	6.0	5.6	5.6
Provisions	1.0	1.1	3.1	2.1	1.8
Tax Rate	35.1	36.2	28.0	25.2	25.2
RoA	1.4	2.6	2.0	2.4	2.6
RoE	12.2	19.1	15.1	17.4	19.4

DuPont (% avg assets)	FY18	FY19	FY20E	FY21E	FY22E
Interest income	16.4	15.6	12.3	11.8	12.3
Interest expense	9.1	8.5	6.6	6.0	6.3
NII	7.3	7.1	5.7	5.8	6.0
Other income	0.3	2.6	3.3	3.2	3.0
Total income	7.6	9.7	9.0	8.9	9.1
Operating expenses	4.7	5.0	4.6	4.6	4.6
Employees	3.2	3.5	3.3	3.2	3.1
Others	1.5	1.5	1.3	1.3	1.4
РРОР	2.9	4.7	4.4	4.4	4.5
Provisions	0.8	0.7	1.6	1.1	1.0
РВТ	2.2	4.0	2.8	3.2	3.5
Тах	0.8	1.5	0.8	0.8	0.9
PAT	1.4	2.6	2.0	2.4	2.6

Source: Company, Centrum Research estimates

Balance Sheet (Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Financial assets	61,096	66,082	58,600	73,223	93,671
Cash	4,458	10,039	6,019	6,571	6,899
Bank balance	6,374	6,940	5,556	5,973	7,665
Loans	48,452	44,601	41,195	54,377	71,044
Investment	1,486	4,219	5,556	5,973	7,665
Others	326	284	274	329	398
Non-financial assets	1,530	992	764	986	1,265
Deferred tax assets	887	312	278	418	537
Fixed Assets	360	430	417	448	575
Others	283	250	69	119	153
Total Assets	62,626	67,073	59,364	74,209	94,936
Financial liabilities	53,436	55,230	46,997	58,424	77,421
Debt securities	9,193	9,759	8,358	10,396	13,783
Borrowings	38,624	37,200	31,862	39,628	52,540
Subordinated Debt	3,692	5,392	4,618	5,744	7,615
Others	1,927	2,879	2,159	2,656	3,482
Non-financial liabilities	270	329	243	304	389
Current tax liabilities	91	118	87	109	139
Provisions	102	135	100	125	160
Others	77	76	56	70	90
Total equity	8,919	11,514	12,123	15,481	17,126
Share capital	473	485	485	535	535
Other equity	8,446	11,029	11,638	14,946	16,592
Total Liabilities	62,626	67,073	59,364	74,209	94,936
Balance Sheet ratios (%)					
Debt / Equity	5.8	4.5	3.7	3.6	4.3
Assets / Equity	7.0	5.8	4.9	4.8	5.5
Cash / Borrowings	0.2	0.3	0.3	0.2	0.2
Capital (%)	3,385	362			
CRAR	21.2	28.5	31.2	28.6	25.6
Tier-1	14.6	19.9	23.1	21.1	18.9
Tier-2	6.6	8.6	8.6	7.4	6.7
Asset quality (%)					
GNPA (Rs mn)	2,152	1,779	2,539	2,956	3,490
NNPA (Rs mn)	742	1,061	889	994	1,198
GNPA	4.2	2.8	3.6	3.3	3.1
NNPA	1.5	1.7	1.2	1.1	1.1
PCR	65.5	40.4	65.0	66.4	65.7
NNPA/ Equity	8.3	9.2	7.3	6.4	7.0
Per share (Rs)					
EPS	17.4	40.2	36.7	44.8	59.2
BVPS	188.7	237.3	249.8	289.5	320.3
ABVPS	173.0	215.4	231.5	270.9	297.9
Valuation (x)					
P/E	20.4	7.7	5.0	4.1	3.1
P/BV	1.9	1.3	0.7	0.6	0.6
P/ABV	2.1	1.4	0.8	0.7	0.6

#### Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the fore going limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Gaurav Jani & Mr. Rahul Nandwani, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

#### **Ratings definitions**

Our ratings denote the following 12-month forecast returns:

Buy – The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5-+5% returns.

Sell – The stock is expected to deliver <-5% returns.

#### Satin Creditcare



Source: Bloomberg

		Disclosure of Interest Statement			
1	1 Business activities of Centrum Broking Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivative Limited (CBL) Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI register Portfolio Manager.				
2	Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in secu	urities market.		
3	Registration status of CBL:	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)			
			Satin Creditcare		
4	Whether Research analyst's or relatives'	have any financial interest in the subject company and nature of such financial interest	No		
5	Whether Research analyst or relatives ha immediately preceding the date of public	we actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month cation of the document.	No		
6	Whether the research analyst or his relation	ives has any other material conflict of interest	No		
7	Whether research analyst has received which such compensation is received	any compensation from the subject company in the past 12 months and nature of products / services for	No		
8	Whether the Research Analyst has receiv research report	ved any compensation or any other benefits from the subject company or third party in connection with the	No		
9	Whether Research Analysts has served as	s an officer, director or employee of the subject company	No		
10	Whether the Research Analyst has been e	engaged in market making activity of the subject company.	No		
11	Whether it or its associates have manage	d or co-managed public offering of securities for the subject company in the past twelve months;	No		
12	Whether it or its associates have receiv company in the past twelve months;	ed any compensation for investment banking or merchant banking or brokerage services from the subject	No		
13	Whether it or its associates have received services from the subject company in the	d any compensation for products or services other than investment banking or merchant banking or brokerage past twelve months;	No		

#### Member (NSE and BSE). Member MSEI (Inactive)

#### Single SEBI Regn No.: INZ000205331

# Depository Participant (DP)

CDSL DP ID: 120 – 12200 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

#### SEBI REGN NO.: INP000004383

## Research Analyst SEBI Registration No. INH000001469

Mutual Fund Distributor AMFI REGN No. ARN- 147569

Website: www.centrum.co.in Investor Grievance Email ID: investor.grievances@centrum.co.in

#### **Compliance Officer Details:**

Ashok D Kadambi (022) 4215 9937; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)

Registered Office Address Bombay Mutual Building , 2nd Floor, Dr. D. N. Road, Fort, Mumbai - 400 001 Corporate Office & Correspondence Address Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai 400 098. Tel: (022) 4215 9000 Fax: +91 22 4215 9344

	Centrum Broking Institutional Equities Team Details						
Nischal Maheshwari	CEO	nischal.maheshwari@centrum.co.in	+91-22-4215 9841				
Research Analyst	Sector	E-mail	Phone number				
Sneha Prashant	Auto & Auto Ancillary	sneha.prashant@centrum.co.in	+91-22-4215 9263				
Gaurav Jani	BFSI	gaurav.jani@centrum.co.in	+91-22-4215 9110				
Milind S Raginwar	Cement & Metals	milind.raginwar@centrum.co.in	+91-22-4215 9201				
Shirish Pardeshi	FMCG	shirish.pardeshi@centrum.co.in	+91-22-4215 9634				
Ashish Shah	Infra & Aviation	shah.ashish@centrum.co.in	+91-22-4215 9021				
Madhu Babu	IT	madhu.babu@centrum.co.in	+91-22-4215 9855				
Probal Sen	Oil & Gas	Probal.sen@centrum.co.in	+91-22-4215 9001				
Cyndrella Carvalho	Pharma	cyndrella.carvalho@centrum.co.in	+91-22-4215 9643				
Sparsh Chhabra	Economist	sparsh.chhabra@centrum.co.in	+91-22-4215 9035				
Joaquim Fernandes	Quant	Joaquim.Fernandes@centrum.co.in	+91-22-4215 9363				
Equity Sales	Designation	Email	Phone number				
Rajesh Makharia	Director	rajesh.makharia@centrum.co.in	+91-22-4215 9854				
Paresh Shah	MD	paresh.shah@centrum.co.in	+91-22-4215 9617				
Anil Chaurasia	Sr. VP	anil.chaurasia@centrum.co.in	+91-22-4215 9631				
Himani Sanghavi	AVP	himani.sanghavi@centrum.co.in	+91-22-4215 9082				
Saahil Harwani	Associate	saahil.harwani@centrum.co.in	+91-22-4215 9623				